Serina Therapeutics, Inc.
SER· NYSE
Released Aug 14, 2023, after the close
10-Q filed Aug 14, 2023, 45 days after period end · 0001493152-23-028478
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $7.00K | $12.00K | $37.00K | $45.00K |
| Net Income | $808.00K | -$2.62M | -$2.47M | -$2.69M |
| EPS Diluted |
Serina Therapeutics, Inc. · CIK 1708599 · Engraved from SEC EDGAR
| $0.11 |
| -$0.07 |
| -$0.07 |
| -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.